Genentech Opens First BPCIA Fight Over Xolair Biosimilar ADL-018
Genentech's Delaware complaint alleging nine patents against Kashiv and Amneal over proposed omalizumab biosimilar ADL-018 is reported as the first BPCIA suit on this product, an early read on the § 262 pathway.
On October 16, 2026, Genentech filed BPCIA Litigation No. 1:26-cv-01343 in the District of Delaware against Kashiv and Amneal, alleging that their proposed Xolair (omalizumab) biosimilar, ADL-018, infringes nine patents. Venable describes the filing as the first litigation brought against this biosimilar; the precise scope of that "first" — first against ADL-018 rather than first of any kind — is not fully specified in the available reporting.
Why sophisticated counsel care: BPCIA litigation under 35 U.S.C. § 262 is the principal channel biologics developers use to test challengers' patent positions before launch, and omalizumab is a high-revenue immunology product where biosimilar entry is a material commercial variable for both innovator and filer clients. A nine-patent assertion shows how an innovator will package its biologic patent estate in the § 262 setting, and how quickly a challenger will respond.
What to watch: the defendants' answers and any early motion practice, including disputes over the § 262 patent-list framework; whether the statutory stay against launch remains in place through trial; and whether parallel suits, additional patent families, or an early settlement emerge. With no launch at issue yet, the commercial stakes are prospective rather than immediate.